1050602-61-3

Basic information

• Product Name: 2-Chloro-N-cyclopropyl-5-(trifluoroMethyl)pyriMidin-4-aMine
• Synonyms: 2-Chloro-N-cyclopropyl-5-(trifluoroMethyl)pyriMidin-4-aMine
• CAS NO: 1050602-61-3
• Molecular Formula: C₈H₇ClF₃N₃
• Molecular Weight: 237.6094896
• Mol File: 1050602-61-3.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 353.3±42.0 °C(Predicted)
• Appearance: /
• Density: 1.583±0.06 g/cm3(Predicted)
• PKA: 0.86±0.10(Predicted)
• CAS DataBase Reference: 2-Chloro-N-cyclopropyl-5-(trifluoroMethyl)pyriMidin-4-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-N-cyclopropyl-5-(trifluoroMethyl)pyriMidin-4-aMine(1050602-61-3)
• EPA Substance Registry System: 2-Chloro-N-cyclopropyl-5-(trifluoroMethyl)pyriMidin-4-aMine(1050602-61-3)

Safety Data

• Hazardous Substances Data: 1050602-61-3(Hazardous Substances Data)

Usage

General Description

2-Chloro-N-cyclopropyl-5-(trifluoroMethyl)pyriMidin-4-aMine is a chemical compound with the molecular formula C9H9ClF3N5. It is a pyrimidine derivative with a cyclopropyl group and a trifluoromethyl group attached to the pyrimidine ring. 2-Chloro-N-cyclopropyl-5-(trifluoroMethyl)pyriMidin-4-aMine has potential biological and pharmaceutical applications, as it may act as a drug or intermediate in the synthesis of pharmaceuticals. Its chemical properties and structure make it of interest for further research and development in the pharmaceutical industry.

Upstream product

• 3932-97-6 2,4-dichloro-5-trifluoromethylpyrimidine 
• 765-30-0 Cyclopropylamine 

Downstream Products

• 1401423-22-0 (4-(4-(cyclopropylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-2-fluoro-5-methoxyphenyl)(morpholino)methanone 
• 1401423-44-6 C₁₆H₁₄F₄N₄O₃ 

Relevant articles and documents

Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer

Inhibition of autophagy, the major cellular recycling pathway in mammalian cells, is a promising strategy for the treatment of triple-negative breast cancer (TNBC). We previously reported SBI-0206965, a small molecule inhibitor of unc-51-like autophagy activating kinase 1 (ULK1), which is a key regulator of autophagy initiation. Herein, we describe the design, synthesis, and characterization of new dual inhibitors of ULK1 and ULK2 (ULK1/2). One inhibitor, SBP-7455 (compound 26), displayed improved binding affinity for ULK1/2 compared with SBI-0206965, potently inhibited ULK1/2 enzymatic activity in vitro and in cells, reduced the viability of TNBC cells and had oral bioavailability in mice. SBP-7455 inhibited starvation-induced autophagic flux in TNBC cells that were dependent on autophagy for survival and displayed synergistic cytotoxicity with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib against TNBC cells. These data suggest that combining ULK1/2 and PARP inhibition may have clinical utility for the treatment of TNBC.

PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE

Compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3 and A are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease

2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE

Specific Compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein m, X, R, R2, R3, R, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.